Your browser is no longer supported. Please, upgrade your browser.
Settings
IBIO [AMEX]
iBio, Inc.
Index- P/E- EPS (ttm)-0.13 Insider Own0.99% Shs Outstand217.00M Perf Week-11.08%
Market Cap185.97M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float215.73M Perf Month-31.60%
Income-23.50M PEG- EPS next Q-0.05 Inst Own20.10% Short Float6.92% Perf Quarter-34.93%
Sales2.40M P/S77.49 EPS this Y80.30% Inst Trans-0.03% Short Ratio5.01 Perf Half Y-40.72%
Book/sh0.50 P/B1.60 EPS next Y- ROA-17.00% Target Price2.50 Perf Year-59.58%
Cash/sh0.42 P/C1.92 EPS next 5Y- ROE-23.40% 52W Range0.78 - 2.83 Perf YTD-23.78%
Dividend- P/FCF- EPS past 5Y37.00% ROI-22.00% 52W High-71.87% Beta-6.06
Dividend %- Quick Ratio15.70 Sales past 5Y20.10% Gross Margin71.30% 52W Low1.92% ATR0.05
Employees18 Current Ratio15.70 Sales Q/Q-54.50% Oper. Margin- RSI (14)24.52 Volatility4.74% 5.43%
OptionableYes Debt/Eq0.30 EPS Q/Q100.70% Profit Margin- Rel Volume0.89 Prev Close0.80
ShortableYes LT Debt/Eq0.29 EarningsSep 27 BMO Payout- Avg Volume2.98M Price0.80
Recom2.00 SMA20-16.64% SMA50-27.56% SMA200-44.69% Volume1,434,443 Change-0.52%
Jan-22-21Initiated Cantor Fitzgerald Overweight $3
Jun-26-20Initiated Alliance Global Partners Buy $2.55
Oct-02-21 07:31AM  
Sep-27-21 07:30AM  
Sep-20-21 04:30PM  
07:30AM  
Sep-07-21 04:30PM  
Aug-26-21 07:00AM  
Aug-25-21 11:16AM  
07:30AM  
Jul-15-21 05:10PM  
Jul-09-21 06:10AM  
Jul-08-21 04:15PM  
Jun-18-21 09:13PM  
Jun-09-21 04:30PM  
May-19-21 04:30PM  
May-17-21 07:00AM  
06:15AM  
May-10-21 08:15AM  
May-08-21 10:15AM  
May-07-21 11:52AM  
07:01AM  
May-05-21 08:42PM  
May-04-21 05:00PM  
Mar-12-21 05:13PM  
Mar-09-21 04:30PM  
Feb-17-21 04:30AM  
Feb-16-21 04:05PM  
02:30PM  
08:00AM  
Feb-15-21 01:34AM  
Feb-12-21 11:57AM  
Feb-09-21 04:30PM  
Jan-29-21 10:46AM  
Jan-22-21 02:02PM  
Dec-28-20 07:30AM  
Dec-10-20 04:30PM  
Dec-08-20 08:55AM  
Dec-07-20 04:01PM  
Dec-04-20 11:40AM  
Dec-01-20 04:30PM  
Nov-27-20 07:10PM  
Nov-25-20 12:12PM  
Nov-24-20 07:30AM  
Nov-20-20 10:13AM  
Nov-16-20 04:05PM  
Nov-15-20 06:14AM  
Nov-13-20 10:48AM  
Nov-12-20 08:00AM  
Nov-05-20 04:30PM  
Nov-03-20 07:30AM  
Oct-29-20 06:29AM  
Oct-15-20 04:05PM  
07:30AM  
Oct-14-20 04:05PM  
Oct-13-20 04:05PM  
Oct-05-20 07:30AM  
Oct-02-20 01:04PM  
01:04PM  
01:01PM  
01:01PM  
08:09AM  
07:00AM  
Sep-21-20 02:55PM  
Sep-18-20 01:58PM  
Sep-09-20 11:58AM  
08:45AM  
Sep-03-20 03:29PM  
Aug-28-20 01:58PM  
07:15AM  
05:01AM  
Aug-24-20 08:42AM  
Aug-19-20 12:52PM  
Aug-14-20 04:55PM  
Aug-10-20 07:15AM  
Jul-20-20 10:17AM  
Jul-10-20 03:19PM  
11:24AM  
Jul-02-20 01:56PM  
Jun-27-20 11:55AM  
Jun-26-20 02:32PM  
11:48AM  
08:18AM  
06:45AM  
Jun-24-20 06:45AM  
Jun-18-20 10:50PM  
Jun-05-20 06:01AM  
Jun-04-20 07:00AM  
May-29-20 09:10AM  
May-27-20 11:45AM  
May-22-20 09:05AM  
May-21-20 02:44PM  
Apr-28-20 03:44PM  
Apr-27-20 04:15PM  
Apr-24-20 07:00AM  
Apr-09-20 07:30AM  
Apr-03-20 05:01AM  
Mar-26-20 04:20PM  
07:30AM  
Mar-20-20 11:38AM  
07:30AM  
Mar-18-20 08:00AM  
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.